Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft

Journal of Clinical Oncology

Volumn 30, Issue 4, 2012, Pages

  Morelli, M Pia ^a   Calvo, Emiliano ^b   Ordoñez, Esther ^c   Wick, Michael J ^d   Viqueira, Belen Rubio ^a   Lopez Casas, Pedro P ^a   Bruckheimer, Elizabeth ^e   Calles Blanco, Antonio ^a   Sidransky, David ^f   Hidalgo, Manuel ^b,f  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b UNIVERSIDAD SAN PABLO CEU   (Spain)

^c South Texas Accelerated Research Therapeutics Madrid Phase I Unit   (Spain)

^d South Texas Accelerated Research Therapeutics   (United States)

^e Champions Biotechnology   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BORTEZOMIB; DACOMITINIB; DASATINIB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIGITUMUMAB; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; IMATINIB; IRINOTECAN; K RAS PROTEIN; LAPATINIB; MITOMYCIN C; NAVELBINE; OXALIPLATIN; PACLITAXEL; PLATINUM; SOMATOMEDIN C RECEPTOR; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; TOPOTECAN; TRASTUZUMAB; VORINOSTAT;

ADENOID CYSTIC CARCINOMA; ADULT; ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN DAMAGE; BRAIN METASTASIS; CANCER GRAFT; CANCER INHIBITION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIARRHEA; DRUG WITHDRAWAL; FEMALE; GENE AMPLIFICATION; GENE MUTATION; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TISSUE SECTION; TUMOR VOLUME;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARCINOMA, ADENOID CYSTIC; CLINICAL TRIALS, PHASE I AS TOPIC; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASM METASTASIS; NEOPLASM STAGING; QUINAZOLINONES; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84856695586     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.9678     Document Type: Article

References (15)

1. Rubio-Viqueira B, Jimeno A, Cusatis G, et al: An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 12:4652-4661, 2006 (Pubitemid 44297818)
2. Engelman JA, Zejnullahu K, Gale CM, et al: PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 67:11924-11932, 2007
3. Renehan A, Gleave EN, Hancock BD, et al: Long-term follow-up of over 1000 patients with salivary gland tumours treated in a single centre. Br J Surg 83:1750-1754, 1996 (Pubitemid 26421878)
4. Spiro RH: Distant metastasis in adenoid cystic carcinoma of salivary origin. Am J Surg 174:495-498, 1997
5. Spiro RH: Management of malignant tumors of the salivary glands. Oncology (Williston Park) 12:671-680; discussion 683, 1998
6. Terhaard CH, Lubsen H, Van der Tweel I, et al: Salivary gland carcinoma: Independent prognostic factors for locoregional control, distant metastases, and overall survival: Results of the Dutch head and neck oncology cooperative group. Head Neck 26:681-692; discussion 692-693, 2004
7. Laurie SA, Ho AL, Fury MG, et al: Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: A systematic review. Lancet Oncol 12:815-824, 2011
8. Hotte SJ, Winquist EW, Lamont E, et al: Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: A Princess Margaret Hospital phase II consortium study. J Clin Oncol 23:585-590, 2005 (Pubitemid 46224236)
9. Pfeffer MR, Talmi Y, Catane R, et al: A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. Oral Oncol 43:33-36, 2007 (Pubitemid 46162246)
10. Locati LD, Bossi P, Perrone F, et al: Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. Oral Oncol 45:574-578, 2009
11. Agulnik M, Cohen EW, Cohen RB, et al: Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 25:3978-3984, 2007 (Pubitemid 47477277)
12. Flaherty KT, Puzanov I, Kim KB, et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819, 2010
13. Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703, 2010
14. Von Hoff DD, LoRusso PM, Rudin CM, et al: Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 361:1164-1172, 2009
15. Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, et al: Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther 10:3-8, 2011